• Open
  • sdadmin
    September 21, 2018 at 10:55 am #1506
    1. WHEREAS, drug overdose is the leading cause of accidental death in the United States with 52,404
    2. drug overdoses in 2015 alone1; and
    1. WHEREAS, Among 47,055 drug overdose deaths that occurred in 2014 in the United States, 28,647
    2. (60.9%) involved an opioid1; and
    1. WHEREAS, Opioids killed more than 33,000 people in 2015, and nearly half died using a prescription
    2. opioid2; and
    1. WHEREAS, Prescription opioid-related overdose deaths and admissions for treatment of opioid use
    2. disorder have increased in parallel with increases in opioids prescribed in the United States, which
    3. quadrupled from 1999 to 20103; and
    1. WHEREAS, The economic burden of prescription opioid overdose, abuse, and dependence is estimated
    2. to be $78.5 billion each year in the United States3; and
    1. WHEREAS, Cannabis can be an effective treatment for pain, greatly reduces the chance of dependence,
    2. and eliminates the risk of fatal overdose compared to opioid-based medications. Medical cannabis
    3. patients report that cannabis is just as effective, if not more, than opioid-based medications for pain;4
    4. and
    1. WHEREAS, The associations between MCLs and any opioid prescribing were statistically significant
    2. when we took the type of MCL into account: states with active dispensaries saw 3.742 million fewer
    3. daily doses filled (95% CI, −6.289 to −1.194); states with home cultivation only MCLs saw 1.792
    4. million fewer filled daily doses (95% CI, −3.532 to −0.052);
    1. WHEREAS, Introduction of medical marijuana laws may be associated with declining prescriptions for
    2. Medicaid enrollees, as the use of prescription drugs in fee-for-service Medicaid was lower in states with
    3. legalized medical cannabis in comparison to those that did not6. Therefore, it be
    1. RESOLVED, that SOMA petition to the AOA to fund research to explore the option of using
    2. cannabinoids as an alternative to opioids for chronic pain management in non-cancer.


    1. Rudd RA, Seth P, David F, Scholl L. Increases in Drug and Opioid-Involved Overdose Deaths — United States, 2010–2015. MMWR Morbidity Mortality Weekly Report 2016;65:1445–1452. DOI: http://dx.doi.org/10.15585/mmwr.mm655051e1
    2. McIver, J. S. (2017). Seeking Solutions to the Opioid Crisis. Pharmacy and Therapeutics, 42(7), 478. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5481299/
    3. Guy GP Jr., Zhang K, Bohm MK, et al. Vital Signs: Changes in Opioid Prescribing in the United States, 2006–2015. MMWR Morb Mortal Wkly Rep 2017;66:697–704. DOI: http://dx.doi.org/10.15585/mmwr.mm6626a4
    4. Reiman, A., Welty, M., & Solomon, P. (2017). Cannabis as a Substitute for Opioid-Based Pain Medication: Patient Self-Report. Cannabis and Cannabinoid Research, 2(1), 160–166. http://doi.org/10.1089/can.2017.0012
    5. Bradford AC, Bradford WD, Abraham A, Bagwell Adams G. Association Between US State Medical Cannabis Laws and Opioid Prescribing in the Medicare Part D Population. JAMA Intern Med. 2018;178(5):667–672. doi:10.1001/jamainternmed.2018.0266
    6. Bradford, A. C., & Bradford, W. D. (2017, May). Medical Marijuana Laws May Be Associated With A Decline In The Number Of Prescriptions For Medicaid Enrollees. Retrieved September 12, 2018, from https://doi.org/10.1377/hlthaff.2016.1135

    7. Submitted by:
      Sophia Ahmad, OMS I – New York Institute of Technology College of Osteopathic Medicine
      Ancy Alexander, OMS II – New York Institute of Technology College of Osteopathic Medicine
      Amanjot Arora, OMS II – New York Institute of Technology College of Osteopathic Medicine
      Mohammed Kazim OMS II – New York Institute of Technology College of Osteopathic Medicine

      Action Taken:


      Effective Time Period: Ongoing